에서 실시간으로 운영 중이에요! 자세히 알아보기

Stereotaxis

STXS

시가총액 US$1.01억

1.01 USD

-0.04

3.81%

장 마감 시점 업데이트됨 10월 16일 PM 4:00 EDT

1일

-3.81%

5일

-9.01%

1개월

-23.48%

3개월

-38.79%

6개월

-49.75%

연초 이후

-56.47%

1년

-66.67%

5년

-82.37%

10년

-69.76%

소개: Stereotaxis Inc is engaged in robotic technologies designed to enhance the treatment of arrhythmias and perform endovascular procedures. The company's mission is the discovery, development, and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced integration of procedural information. The company's revenue generation is derived from the streams of Systems, Disposables, Royalty, and Sublease, of which a majority of revenue is generated from the Disposables, service, and accessories stream.

직원 수: 131

건강관리 의료기기

뉴스

긍정적

중립

부정적

투자 심리 3개월

긍정적 12.5%

중립 75%

부정적 12.5%

Stereotaxis Emerging Digital, AI and Automation Capabilities to be Featured at Heart Rhythm Society's HRX 2026

New digital technologies, including Synchrony and SynX, will be featured at HRX Stereotaxis CEO to join main-stage panel on Autonomous EP Systems ST. LOUIS, Sept.

Stereotaxis Emerging Digital, AI and Automation Capabilities to be Featured at Heart Rhythm Society's HRX 2026

University of Szeged Celebrates Strongest First Month of Robotic Cardiology Program

ST. LOUIS, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that the Electrophysiology team at the University of Szeged in Hungary has successfully treated over 70 patients using the Genesis Robotic Magnetic Navigation system, just over a month after launching its robotic cardiology program.

University of Szeged Celebrates Strongest First Month of Robotic Cardiology Program

Stereotaxis, Inc. (STXS) Q2 2026 Earnings Call Transcript

Stereotaxis, Inc. (STXS) Q2 2026 Earnings Call Transcript

Stereotaxis, Inc. (STXS) Q2 2026 Earnings Call Transcript

Stereotaxis Q2 Earnings Call Highlights

Stereotaxis NYSEAMERICAN: STXS reported second-quarter 2026 revenue of $7.7 million, as growth in sales of its robotic catheter portfolio helped lift recurring revenue to a multiyear high despite lower system revenue and continued supply constraints.

Stereotaxis Q2 Earnings Call Highlights

Zacks Investment Research

Stereotaxis Inc. (STXS) Reports Q2 Loss, Lags Revenue Estimates

Stereotaxis Inc. (STXS) came out with a quarterly loss of $0.05 per share versus the Zacks Consensus Estimate of a loss of $0.03. This compares to a loss of $0.05 per share a year ago.

Stereotaxis Inc. (STXS) Reports Q2 Loss, Lags Revenue Estimates

Stereotaxis Reports 2026 Second Quarter Financial Results & Business Updates

ST. LOUIS, Mo., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported business updates and financial results for the second quarter ended June 30, 2026.

Stereotaxis Reports 2026 Second Quarter Financial Results & Business Updates

Stereotaxis to Report Second Quarter 2026 Financial Results on August 11, 2026

ST. LOUIS, July 21, 2026 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will release financial results for its 2026 second quarter on Tuesday, August 11, 2026 at the close of the U.S. financial markets. The Company will host a conference call and webcast at 4:30 p.m.

Stereotaxis to Report Second Quarter 2026 Financial Results on August 11, 2026

University of Szeged Pioneers First Robotic Cardiology Program in Hungary

First Robotic Magnetic Navigation system installed in Hungary University of Szeged, led by Cardiology Chief Dr. Szili-Torok, expected to treat hundreds of patients annually with all forms of cardiac arrhythmia using precision of robotics ST. LOUIS, July 20, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced the launch of the first advanced robotic cardiology program in Hungary at the University of Szeged in Szeged, Hungary.

University of Szeged Pioneers First Robotic Cardiology Program in Hungary

Stereotaxis Completes Acquisition of Robocath

ST. LOUIS and ROUEN, France, July 09, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it has completed its previously announced acquisition of Robocath, an innovator of robotic technologies for interventional cardiology and neurointerventions.

Stereotaxis Completes Acquisition of Robocath

Stereotaxis Q1 Earnings Call Highlights

Stereotaxis NYSEAMERICAN: STXS said its first-quarter results did not yet reflect what management described as a major commercial transition driven by new regulatory approvals, new catheter products and the launch of its GenesisX robotic system.

Stereotaxis Q1 Earnings Call Highlights

뉴스 순위 보기

Lightweight Charts™를 사용해 가격 차트를 구현했어요.